Compare SWZ & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWZ | ATYR |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.6M | 79.2M |
| IPO Year | N/A | 2015 |
| Metric | SWZ | ATYR |
|---|---|---|
| Price | $6.29 | $0.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 14.2K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.12 | $0.64 |
| 52 Week High | $8.57 | $7.29 |
| Indicator | SWZ | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 63.56 | 43.87 |
| Support Level | $6.20 | $0.66 |
| Resistance Level | $6.31 | $0.74 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 81.82 | 29.11 |
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.